From the reviews:
A strength of this book is its comprehensive and up-to-date presentation of issues pertinent to the evaluation of surrgoate endpoints...This book makes an important contribution to the clinical trials literature... Journal of Biopharmaceutical Statistics, 2006
Many of the chapters deal with real-life data examples and studies involving surrogate outcomes, many written by authors who were directly involved in these studies...The editors have written nice background sections...until a more concise manuscript on this topic is written, this book will remain the most important resource for biostatisticians and researchers in this area. Debajyoti Sinha for the Journal of the American Statistical Association, December 2006
This book is a reflection of the ongoing debate on the definition and use of surrogate markers...I see the book as an invitation to join the debate. There is much work to be done and reading the book might inspire many to participate. It will be useful for researchers in this and related fields, such as joint modeling of longitudinal and survival data and multivariate meta-analysis. The book is well organized, is a pleasure to read, and is very well documented with up-to-date references. Hans C. Van Houwelingen for Bioometrics, September 2006
This edited volume deals with a topic that has been the subject of much debate since publication of Prentice's 1989 attempt to formalize the definition of a surrogate marker or endpoint. ... This work focuses on evaluation of a surrogate endpoint. ... an attempt has been made to maintain common notations whenever possible. The editors have succeeded in producing a very useful book. (V. T. Farewell, Short Book Reviews, Vol. 25 (2), 2005)
I enjoyed readhing the book and I certainly learned a lot about these fascinating areas. The book is suitable as a textbook for a postgraduate course in statistics but is also an invaluable reference for the applied statisticians working in industry, academia, or regulatory authority. (ISCB News Book Reviews, 2008)
